Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
October 2021
Long-term Outcome Of A Randomised Controlled Trial Comparing Tacrolimus With Mycophenolate Mofetil As Induction Therapy For Active Lupus Nephritis
Ann Rheum Dis 2020;79:1070–6
Tacrolimus is non inferior to MMF as an induction therapy for LN.
Two-Year, Randomised, Controlled Trial of Belimumab in Lupus Nephritis
N Engl J Med. 2020;383(12):1117–28.
LN occurs in 25–60% of patients with SLE. However, patients with LN are often excluded from clinical trials of SLE therapies.
A Randomized, Controlled Double-Blind Study Comparing The Efficacy And Safety Of Dose-Ranging Voclosporin With Placebo In Achieving Remission In Patients With Active Lupus Nephritis
Kidney Int 2019;95:219–31
Calcineurin inhibitors have the potential to increase the likelihood of complete renal remission (CRR) when added to standard-of-care induction therapy for LN.
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
Arthritis Rheum. 2002;46(8):2121–31.
Cyclophosphamide (with AZA) produces good long-term results in LN.
Mycophenolate Versus Azathioprine As Maintenance Therapy for Lupus Nephritis
N Engl J Med. 2011;365(20):1886–95
MMF was superior to AZA in maintaining a renal response and preventing relapse in patients with LN who had a response to induction therapy.